{"id":44170,"date":"2022-05-20T15:01:05","date_gmt":"2022-05-20T13:01:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/"},"modified":"2022-05-20T15:01:05","modified_gmt":"2022-05-20T13:01:05","slug":"cortexyme-appoints-dr-philip-low-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/","title":{"rendered":"Cortexyme Appoints Dr. Philip Low to Its Board of Directors"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company\u2019s Board of Directors.\n<\/p>\n

<\/a><\/p>\n

\n\u201cIn conjunction with today\u2019s acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Low\u2019s caliber to our Board of Directors,\u201d said David Lamond, chairman of Cortexyme\u2019s Board of Directors. \u201cHis vast expertise across targeted drug discovery, prolific research abilities, and proven track record as a leading biotech entrepreneur further bolsters the scientific and clinical expertise of the Board, following on the recent addition of neurologist and leading expert in Alzheimer\u2019s and dementia care Dr. Marwan Sabbagh.\u201d\n<\/p>\n

\n\u201cThe Cortexyme team and I share the same passion for challenging the status quo to deliver breakthrough therapeutics,\u201d said Dr. Philip Low. \u201cI look forward to contributing my perspective at the Board level as the newly combined company sets its strategic path forward and delivers much needed innovation to patients suffering from degenerative diseases.\u201d\n<\/p>\n

\nDr. Philip S. Low is the Presidential Scholar in Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low has spent more than 30 years exploring novel methods for targeted drug discovery, including target identification, drug design and synthesis, animal testing, and human clinical evaluation. He has published more than 500 scientific articles and has more than 360 U.S. patents and patents pending. Eight drugs stemming from his research are currently undergoing human clinical trials and seven companies (Endocyte Inc., OnTarget Laboratories Inc., Novosteo Inc., Erythrocure Inc., Umoja Biopharma Inc., Morphimmune Inc. and Eradivir Inc.) have been founded to commercialize these discoveries. Dr. Low has received an NIH MERIT Award, the ACS Award for Cancer Research (Sosnovsky Award), the AACR Award for Outstanding Chemistry in Cancer Research, both of Purdue’s awards for outstanding research (McCoy and Sigma Xi Awards), the University\u2019s highest career achievement award (Morrill Award), the American Chemical Society\u2019s Esselen Award and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University and his PhD in Biochemistry from the University of California, San Diego.\n<\/p>\n

\nAbout Cortexyme<\/b>\n<\/p>\n

\nCortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases. The company\u2019s innovative pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis<\/i>\u2019 role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer\u2019s disease, among others. To learn more about Cortexyme, visit www.cortexyme.com<\/a> or follow @Cortexyme on Twitter.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCortexyme Contact:<\/b>
Stacy Roughan
\n
Cortexyme, Inc.
\n
Vice President, Corporate Communications & Investor Relations
\n
ir@cortexyme.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company\u2019s Board of Directors. \u201cIn conjunction with today\u2019s acquisition … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44170","6":"format-standard","7":"category-industry"},"yoast_head":"\nCortexyme Appoints Dr. Philip Low to Its Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company\u2019s Board of Directors. \u201cIn conjunction with today\u2019s acquisition ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-20T13:01:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220520005049\/en\/1091862\/21\/logo_large_jpg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cortexyme Appoints Dr. Philip Low to Its Board of Directors\",\"datePublished\":\"2022-05-20T13:01:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/\"},\"wordCount\":509,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005049\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/\",\"name\":\"Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005049\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\",\"datePublished\":\"2022-05-20T13:01:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005049\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220520005049\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cortexyme Appoints Dr. Philip Low to Its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company\u2019s Board of Directors. \u201cIn conjunction with today\u2019s acquisition ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-20T13:01:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220520005049\/en\/1091862\/21\/logo_large_jpg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cortexyme Appoints Dr. Philip Low to Its Board of Directors","datePublished":"2022-05-20T13:01:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/"},"wordCount":509,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220520005049\/en\/1091862\/21\/logo_large_jpg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/","name":"Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220520005049\/en\/1091862\/21\/logo_large_jpg.jpg","datePublished":"2022-05-20T13:01:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220520005049\/en\/1091862\/21\/logo_large_jpg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220520005049\/en\/1091862\/21\/logo_large_jpg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-appoints-dr-philip-low-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cortexyme Appoints Dr. Philip Low to Its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44170"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44170\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}